CoChat

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

Open access
Henry, Robert R., Rosenstock, Julio, Logan, Douglas K., Alessi, Thomas R., Luskey, Kenneth, Baron, Michelle A. · 2013 · Diabetes Care
Cited by 43

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: We conducted a randomized, two-stage, 24-week, open-label, phase 2 study in type 2 diabetes inadequately controlled with metformin. Stage I: 155 subjects were randomized to 20 or 40 μg/day of ITCA 650 or Ex-BID 5→10 μg. Stage II: 131 subjects were rerandomized to 20, 40, 60, or 80 μg/day of ITCA 650. Change from baseline for HbA1c, weight, and fasting plasma glucose were evaluated at weeks 12 and 24. RESULTS: HbA1c was significantly lower in all groups after 12 and 24 weeks. Stage I: mean change in HbA1c from a mean baseline of 7.9–8.0% was −0.98, −0.95, and −0.72% for the 20 and 40 μg/day ITCA 650 and Ex-BID groups, respectively, with 63, 65, and 50% of subjects achieving HbA1c levels ≤7% (P < 0.05). Stage II: significant (P < 0.05) reductions in HbA1c (∼1.4% from baseline) were achieved with 60 and 80 μg/day ITCA 650, and 86 and 78% of subjects achieved HbA1c ≤7% at 24 weeks; respectively. Weight was reduced by 2.8–3.7 kg (P < 0.05) at 24 weeks in all except the 20→20 μg/day group. ITCA 650 was well tolerated; nausea was lower and transient with 20 μg/day relative to Ex-BID; and 60 μg/day had the best profile of tolerability and HbA1c lowering. CONCLUSIONS: ITCA 650 significantly reduced HbA1c and weight and was well tolerated. The 20→60 μg/day regimen was considered the best dose for further examination in phase 3.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-2410

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 20

  1. Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis, JAMA, 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
  2. Fakhoury, 2010, A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes, Pharmacology, 86, 44, 10.1159/000314690 · DOI · Paper page
  3. Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials, Eur J Endocrinol, 160, 909, 10.1530/EJE-09-0101 · DOI · Paper page
  4. Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540 · DOI · Paper page
  5. Cooke, 2010, Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization, Curr Med Res Opin, 26, 231, 10.1185/03007990903421994 · DOI · Paper page
  6. Jose, 2010, Exenatide once weekly: clinical outcomes and patient satisfaction, Patient Prefer Adherence, 4, 313
  7. Rohloff, 2008, DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months, J Diabetes Sci Tech, 2, 461, 10.1177/193229680800200316 · DOI
  8. Shyangdan, 2010, Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis, BMC Endocr Disord, 10, 20, 10.1186/1472-6823-10-20 · DOI · Paper page
  9. Taylor, 2011, Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years, BMC Endocr Disord, 11, 9, 10.1186/1472-6823-11-9 · DOI · Paper page
  10. Osterberg, 2005, Adherence to medication, N Engl J Med, 353, 487, 10.1056/NEJMra050100 · DOI · Paper page
  11. Bailey, 2011, Patient adherence to medication requirements for therapy of type 2 diabetes, Int J Clin Pract, 65, 314, 10.1111/j.1742-1241.2010.02544.x · DOI · Paper page
  12. Mann, 2009, Predictors of adherence to diabetes medications: the role of disease and medication beliefs, J Behav Med, 32, 278, 10.1007/s10865-009-9202-y · DOI · Paper page
  13. Rubin, 2009, Barriers to insulin injection therapy: patient and health care provider perspectives, Diabetes Educ, 35, 1014, 10.1177/0145721709345773 · DOI · Paper page
  14. Kuritzky, 2009, Overcoming barriers to insulin replacement, J Fam Pract, 58, S25
  15. Rubin, 2005, Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus, Am J Med, 118, 27S, 10.1016/j.amjmed.2005.04.012 · DOI · Paper page
  16. Cramer, 2005, The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin?, Diabetes Care, 28, 78, 10.2337/diacare.28.1.78 · DOI · Paper page
  17. Donnelly, 2007, Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes, QJM, 100, 345, 10.1093/qjmed/hcm031 · DOI · Paper page
  18. Fabunmi, 2009, Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine, Curr Med Res Opin, 25, 777, 10.1185/03007990802715199 · DOI · Paper page
  19. Alvarez Guisasola, 2008, Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study, Diabetes Obes Metab, 10, 25, 10.1111/j.1463-1326.2008.00882.x · DOI · Paper page
  20. Ross, 2011, Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes, Curr Med Res Opin, 27, 13, 10.1185/03007995.2011.621416 · DOI · Paper page

Cited by

See all 43

Metadata

Authors
Henry, R. R., Rosenstock, J., Logan, D. K., Alessi, T. R., Luskey, K., & Baron, M. A.
Venue
Diabetes Care
Published
2013-08-13
Volume
36
Issue
9
Pages
2559-2565
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2123269659
Cited by
43
References
5
FWCI
3.54
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.